M&A and Investments in Life Sciences

Syncona

Advised on its investment in connection with the EUR 80 million Series B financing round of iOnctura, a clinical stage biopharmaceutical company focused on delivering innovative cancer treatments to patients with unmet medical need. Syncona is a leading healthcare company focused on founding, building and funding a portfolio of global leaders in life sciences, is listed on the London Stock Exchange and has a net asset value of GBP 1.3 billion.

Venture capital consortium consisting of Merck Ventures, Stichting Depositary INKEF Investment Fund, Bioqube Ventures and Taiho Ventures

Advised on a EUR 19,5 million Series Seed Investment in Anavo Therapeutics. Anavo will be active in the field of research, discovery, development, manufacturing and sale of drugs modulating phosphatases for oncology and immunology indications and its goal is to become the go-to company for phosphatase-based target deals.

Brocacef

Advised on the acquisition of 20 Dutch pharmacies from Ceban. In return Ceban Compounding, part of Ceban Pharmaceuticals, acquires the compounding business of Brocacef Hospital Pharmacy, part of Brocacef Group. Brocacef is a large Dutch pharmacy chain and wholesaler,

GPW Group

Carl Zeiss

Advised Carl Zeiss Meditec on the acquisition of Dutch Ophthalmic Research Center (DORC) from investment firm Eurazeo for EUR 985 million. DORC is one of the world’s leading suppliers of equipment, instruments and liquids for ophthalmic surgery. The company improves eye surgery globally and maximises surgeon control by providing innovative quality approaches for eye disorders. Carl Zeiss Meditec is one of the world's leading medical technology companies. This transaction was awarded the Best Deal award at the M&A Awards 2024, organised by mena.nl.

Immatics

Advised on the business combination with Arya Sciences Acquisition Corporation and listing on NASDAQ. The Immatics shares and warrants are now traded under the symbol “IMTX” and the symbol “IMTXW” on the Nasdaq Capital Market. The proceeds from this transaction were approximately USD 253 million, which included funds held in Arya’s trust account and the common stock private investment in public equity (PIPE) financing contributed by a group of leading US healthcare institutional investors.

EPIRUS Biopharmaceuticals

Advised on the sale of EPIRUS Biopharmaceuticals to the Polpharma Group, the leading pharmaceutical company in Poland and one of the leaders in Central and Eastern Europe. EPIRUS Biopharmaceuticals offers services, including cell line development using its proprietary, high-performance CHOBC® platform, upstream process development, downstream process development and analytical services, including glycan analytics and mass spectrometry.

Curetis

Advised on its initial public offering on Euronext in Amsterdam. Curetis is a molecular diagnostics company which focuses on the development and commercialisation of reliable, fast and cost-effective products for diagnosing severe infectious diseases. The diagnostic solutions of Curetis enable rapid multi-parameter pathogen and antibiotic resistance marker detection in only a few hours, a process that today can take up to days or even weeks with other techniques.

Promicol Biotech

Advised on its EUR 5 million financing round. The funds are earmarked for the development and marketing of new products. Promicol is producer of a large array of (patented) products for rapid testing of microbial load.